Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | WNT3A | P56704 | 2/20 | 0.35 |
| ▸ | RAF1 | P04049 | 6/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29836554 | 1.00 | NR1H2 (0.38) | NR1H2IGF1RUCHL1NPC1RAB9A | |
| SCHEMBL23762175 | 0.97 | UCHL1 (0.35) | NR1H2IGF1RUCHL1NPC1RAB9A | |
| SCHEMBL23762161 | 0.96 | PIP5K1C (0.36) | NR1H2IGF1RUCHL1NPC1RAB9A | |
| SCHEMBL23751185 | 0.92 | MAPT (0.37) | PIK3C3MAPT | |
| SCHEMBL21593191 | 0.92 | NR1H2 (0.38) | NR1H2IGF1RHDAC8WNT3AMMP1 | |
| SCHEMBL21593118 | 0.91 | NR1H2 (0.36) | NR1H2IGF1RMMP1MMP13ADAM17 | |
| SCHEMBL21593189 | 0.90 | NR1H2 (0.37) | NR1H2IGF1RHDAC8WNT3AMAPT | |
| SCHEMBL23762177 | 0.90 | WNT3A (0.35) | NR1H2IGF1RUCHL1NPC1RAB9A | |
| SCHEMBL23762216 | 0.90 | ACACB (0.36) | NR1H2IGF1RNPC1RAB9AHDAC8 | |
| SCHEMBL21593221 | 0.90 | UCHL1 (0.36) | NR1H2IGF1RUCHL1HDAC8WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NR1H2 1422/4885IGF1R 2725/4885UCHL1 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.